官方服务：
资源简介：
Alpelisib-related adverse events from the FDA Adverse Event Reporting System database (FAERS)
应用场景：
创建时间：
2024-01-23
相关数据集
FDA Adverse Event Reporting System Quarterly Data Extract Files
Includes data files and supplemental information. Supplemental information includes a reproducible RMarkdown file, an Excel sheet with metadata, and complete webpage files. From the FAERS Q
DataCite Commons2025-03-17 更新740
Supplementary Material for: Severe Late-onset Neutropenia in a Pregnant Patient with Multiple Sclerosis After Ocrelizumab
Introduction: Ocrelizumab is a recombinant humanized anti-CD20 monoclonal antibody used to treat multiple sclerosis. Late-onset neutropenia, absolute neutrophil count < 1.5x109/L that develops >
DataCite Commons2025-06-01 更新180
New and incremental FDA black box warnings from 2008 to 2015
Background : The boxed warning (also known as ‘black box warning [BBW]’) is one of the strongest drug safety actions that the U.S. Food & Drug Administration (FDA) can implement, and often w
DataCite Commons2020-08-31 更新110
Supplementary Material for: Case Report: Sorafenib-induced Capillary Leak Syndrome
Capillary leak syndrome is a rare life-threatening disorder of acute endothelial hyperpermeability. It consists of initial fluid extravasation resulting in hypotension, hypoalbuminemia and hemoconcent
DataCite Commons2023-10-13 更新280
Supplementary Material for: Exacerbation of diabetic retinopathy following hypoxia-inducible factor-prolyl hydroxylase inhibitor administration: A Case Report
Introduction Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors, used in the treatment of renal anemia, hold the potential to increase the production of vascular endothelial growth factor
DataCite Commons2024-02-26 更新140
